Tonabersat
Phase 2Small molecule
Tonabersat is one of 47 small molecule programs targeting Headache. It is currently in Phase 2.
3
Indications
5
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Biaxin
AbbViePreclinical
Tonabersat
IInflammx Therapeutics Inc
Phase 2
Angiomax
BBaxter Healthcare Corporation
Preclinical
Rayaldee
OOrganon and Co
Preclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Statins
SanofiPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Olokizumab
UCBPreclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Headache2 trials
COVID-191 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tonabersat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IInflammx Therapeutics Inc